Jurriaan Dekkers Sells 4,000 Shares of Faron Pharmaceuticals Oy (LON:FARN) Stock

Faron Pharmaceuticals Oy (LON:FARN) insider Jurriaan Dekkers sold 4,000 shares of Faron Pharmaceuticals Oy stock in a transaction dated Monday, January 12th. The stock was sold at an average price of GBX 182, for a total value of £7,280.

Faron Pharmaceuticals Oy Stock Performance

LON:FARN opened at GBX 180 on Thursday. The company has a debt-to-equity ratio of 922.55, a quick ratio of 1.09 and a current ratio of 1.45. Faron Pharmaceuticals Oy has a fifty-two week low of GBX 146 and a fifty-two week high of GBX 270. The company has a 50 day simple moving average of GBX 183.35 and a two-hundred day simple moving average of GBX 192.41. The company has a market capitalization of £205.96 million, a PE ratio of -6.67 and a beta of 0.36.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.